Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -568.80% is 111% below its 5-year average of -269.75%, near the low end of its 5-year range (-6552.86%–16133.75%).
41.44% above its 12-month average of -971.30%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -183.48%.
NET PROFIT MARGIN
-568.80%
NET PROFIT MARGIN AVG TTM
-971.30%
NET PROFIT MARGIN AVG 3Y
-693.86%
NET PROFIT MARGIN AVG 5Y
-269.75%
NET PROFIT MARGIN AVG 10Y
0.00%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+41.44%
CURRENT VS 3Y AVG
+18.02%
CURRENT VS 5Y AVG
-110.86%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-162414.29%
vs the sector median at left
X4 Pharmaceuticals, Inc.
Market Cap
$261.27M
Net Profit Margin
-568.80%
TTM Avg
-971.30%
3Y Avg
-693.86%
5Y Avg
-269.75%
Market Cap
$261.43M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-5482.65%
5Y Avg
-3802.53%
Market Cap
$262.92M
Net Profit Margin
-62.59%
TTM Avg
-99.90%
3Y Avg
-225.27%
5Y Avg
-207.41%
Market Cap
$259.56M
Net Profit Margin
-43.70%
TTM Avg
-35.13%
3Y Avg
-15.36%
5Y Avg
-13.33%
Market Cap
$259.49M
Net Profit Margin
-28.99%
TTM Avg
-27.18%
3Y Avg
-27.76%
5Y Avg
-23.20%
Market Cap
$259.14M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$259.12M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-2265.94%
5Y Avg
-2185.44%
Market Cap
$258.63M
Net Profit Margin
-6388.20%
TTM Avg
0.00%
3Y Avg
-1230.00%
5Y Avg
-820.00%
Market Cap
$264.25M
Net Profit Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| X4 Pharmaceuticals, Inc. (XFOR) | $261.27M | -568.80% | -971.30% | -693.86% | -269.75% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | 0.00% | 0.00% | -5482.65% | -3802.53% |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | -62.59% | -99.90% | -225.27% | -207.41% |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | -43.70% | -35.13% | -15.36% | -13.33% |
| Treace Medical Concepts, Inc. (TMCI)vs › | $259.49M | -28.99% | -27.18% | -27.76% | -23.20% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.14M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $259.12M | 0.00% | 0.00% | -2265.94% | -2185.44% |
| Palisade Bio, Inc. (PALI)vs › | $258.63M | -6388.20% | 0.00% | -1230.00% | -820.00% |
| Scribe Therapeutics Inc. (SCTX)vs › | $264.25M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.78M | -10994.73% | -520.92% | -360.66% | -288.77% |
Operating Margin
-247.4%
Net Profit Margin
-568.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -183.48% |
| 2026-03-31 | -747.45% |
| 2025-12-31 | -931.66% |
| 2025-09-30 | -1689.24% |
| 2025-06-30 | -1304.66% |
| 2025-03-31 | 0.98% |
| 2024-12-31 | -2776.92% |
| 2024-09-30 | -6552.86% |
| 2024-06-30 | 16133.75% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | -371.27% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-03-31 | 0.00% |